NCT00642031View on ClinicalTrials.gov

Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Hematologic MalignanciesLeukemia
Interventions
DRUG

Triciribine

15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center, Tampa

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

VioQuest Pharmaceuticals

INDUSTRY

lead

Prescient Therapeutics, Ltd.

INDUSTRY

NCT00642031 - Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter